Skip links

Veopoz™ (pozelimab-bbfg)

Full Name Veopoz™ (pozelimab-bbfg)
Drug Veopoz
Manufacturer Regeneron Pharmaceuticals
Route of Administration Intravenous
Site of Care Healthcare Facility
Approved Indication The treatment of adult and pediatric patients 1 year of age and older with CD55-deficient protein-losing enteropathy (PLE), also known as CHAPLE disease
Disease CD55-deficient protein-losing enteropathy (CHAPLE) Disease
Therapeutic Area Allergy & Immunology, Genetics
Enrollment Form Link Veopoz Enrollment Form
Phone Number 800-438-2375
Fax Number 877-440-0891
Product Website